Investors

About

Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

The company’s lead development program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for the treatment of multiple sclerosis, selectively inhibits activated immune cells and shows combined anti-inflammatory, anti-viral and neuroprotective effects. Izumerogant (IMU-935) is a selective inverse agonist of RORγ/RORγt, which inhibits the IL-17 pathway, and is currently being studied in clinical proof-of-concept trials in psoriasis and castration-resistant prostate cancer. IMU-856 is targeted to restore intestinal barrier function and regenerate bowel epithelium, which would be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently being evaluated in a clinical proof-of-concept trial.

Stock Quote
NASDAQIMUX
Fast Facts
  •  Company Founded in 2016
  •  3 Development Programs
  •  Headquartered in New York City
  •  NASDAQ: IMUX
  •  Experts in Selective Oral Drugs in Immunology
Latest News
Mar 2, 2023

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today...

Feb 23, 2023

– Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023 – – Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium in...

Feb 22, 2023

– Long-Term Open-Label Treatment With Vidofludimus Calcium Was Associated With a Low Rate of Confirmed Disability Worsening (CDW) Over Time – – CDW Data Compares Favorably to Historical...

View All

Contact Us

Immunic Therapeutics
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

Rx Communications
Paula Schwartz
Managing Director
+1 917 322 2216
immunic@rxir.com

Subscribe
To receive all investor alerts please subscribe here
* Required Fields